Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV vaccine candidate formulation 1
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
RSV vaccine candidate formulation 1 is a subunit vaccine designed to prevent Respiratory Syncytial Virus (RSV) infection. It is engineered to present the prefusion conformation of the RSV fusion (F) glycoprotein, which is considered the primary target for inducing potent neutralizing antibodies. This recombinant protein antigen, often produced in Chinese hamster ovary (CHO) cells, aims to elicit a robust immune response against both RSV-A and RSV-B subtypes. Some formulations may include an alum adjuvant to enhance immunogenicity. This candidate is typically evaluated in early-stage clinical trials to assess its safety, reactogenicity, and ability to generate an immune response.
- Other names
- RSV vaccine formulation 1
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on RSV vaccine candidate formulation 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV vaccine candidate formulation 1.